DE602004028917D1 - Wasserlösliche thalidominderivate - Google Patents

Wasserlösliche thalidominderivate

Info

Publication number
DE602004028917D1
DE602004028917D1 DE602004028917T DE602004028917T DE602004028917D1 DE 602004028917 D1 DE602004028917 D1 DE 602004028917D1 DE 602004028917 T DE602004028917 T DE 602004028917T DE 602004028917 T DE602004028917 T DE 602004028917T DE 602004028917 D1 DE602004028917 D1 DE 602004028917D1
Authority
DE
Germany
Prior art keywords
chr
thalidomine
derivatives
soluble
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004028917T
Other languages
English (en)
Inventor
Hesheng Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TIAN JIN HEMAY BIO Tech Co Ltd
Original Assignee
TIAN JIN HEMAY BIO Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TIAN JIN HEMAY BIO Tech Co Ltd filed Critical TIAN JIN HEMAY BIO Tech Co Ltd
Publication of DE602004028917D1 publication Critical patent/DE602004028917D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Artificial Filaments (AREA)
DE602004028917T 2003-03-27 2004-03-04 Wasserlösliche thalidominderivate Expired - Lifetime DE602004028917D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB031209947A CN100488959C (zh) 2003-03-27 2003-03-27 水溶性的酞胺哌啶酮衍生物
PCT/CN2004/000167 WO2004085422A1 (fr) 2003-03-27 2004-03-04 Derives de thalidomide hydrosoluble

Publications (1)

Publication Number Publication Date
DE602004028917D1 true DE602004028917D1 (de) 2010-10-14

Family

ID=33035142

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004028917T Expired - Lifetime DE602004028917D1 (de) 2003-03-27 2004-03-04 Wasserlösliche thalidominderivate

Country Status (12)

Country Link
US (1) US7741342B2 (de)
EP (1) EP1607394B1 (de)
JP (1) JP4703554B2 (de)
CN (1) CN100488959C (de)
AT (1) ATE479675T1 (de)
AU (1) AU2004224271B2 (de)
BR (1) BRPI0408675A (de)
CA (1) CA2519051A1 (de)
DE (1) DE602004028917D1 (de)
ES (1) ES2349372T3 (de)
WO (1) WO2004085422A1 (de)
ZA (1) ZA200506797B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7320991B2 (en) 2001-02-27 2008-01-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Analogs of thalidomide as potential angiogenesis inhibitors
WO2005016326A2 (en) * 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
EP1663223B1 (de) 2003-09-17 2014-01-01 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Thalidomid-analoga als tnf-alpha-modulatoren
CN100383139C (zh) 2005-04-07 2008-04-23 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物
KR101696938B1 (ko) 2008-10-29 2017-01-16 셀진 코포레이션 암의 치료에 사용하기 위한 이소인돌린 화합물
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
JP7143295B2 (ja) * 2016-11-24 2022-09-28 ティアンジン ヘメイ ファーマスーティカル サイ－テック カンパニー リミテッド ピペリジン－２，６－ジオン誘導体及びクローン病の治療
WO2019036839A1 (zh) * 2017-08-21 2019-02-28 诺瑞特国际药业股份有限公司 泊马度胺衍生物及其制备方法
CN111499610A (zh) * 2019-01-31 2020-08-07 南京诺瑞特医药科技有限公司 泊马度胺前体药物盐的多晶型物
CN110028439B (zh) * 2019-04-25 2020-11-13 四川大学 邻苯二甲酰亚胺类衍生物及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580641B1 (de) * 1991-04-17 1996-12-27 Grünenthal GmbH Neue thalidomidderivate, ein verfahren zu deren herstellung sowie die verwendung derselben in arzneimitteln
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
CN100383139C (zh) * 2005-04-07 2008-04-23 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物

Also Published As

Publication number Publication date
ATE479675T1 (de) 2010-09-15
EP1607394A4 (de) 2008-06-25
JP2006521295A (ja) 2006-09-21
JP4703554B2 (ja) 2011-06-15
CN1534035A (zh) 2004-10-06
WO2004085422A1 (fr) 2004-10-07
EP1607394B1 (de) 2010-09-01
US20060094730A1 (en) 2006-05-04
EP1607394A1 (de) 2005-12-21
US7741342B2 (en) 2010-06-22
AU2004224271A1 (en) 2004-10-07
BRPI0408675A (pt) 2006-03-28
ES2349372T3 (es) 2010-12-30
CN100488959C (zh) 2009-05-20
AU2004224271B2 (en) 2010-02-18
ZA200506797B (en) 2006-05-31
CA2519051A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
DE69528005T2 (de) Prolineamid-Derivate
DE69820248D1 (de) Pyrrolidin-derivate die eine phospholipase-a2-hemmende wirkung haben
NO20053644L (no) (2S)-2-[(4S)-4-(2,2-difluorvinyl)-2-oksopyrrolidinyl ]butanamid og farmasoytisk preparat
ATE126795T1 (de) Benzopyranderivate und verfahren zu ihrer herstellung.
CY1108085T1 (el) Υποκατεστημενα παραγωγα 1,3-διφαινυλπροπ-2-εν-1-ονης παρασκευη και χρησης αυτων
PA8518701A1 (es) Derivados de tiofeno utiles como agentes anticancerosos
AR022469A1 (es) Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevas sustancias
DK1041072T3 (da) Dioxocyclopentylhydroxamsyrer
ATE321770T1 (de) Pseudoerythromycin-derivate
DE602004028917D1 (de) Wasserlösliche thalidominderivate
DE69727915D1 (de) Substituierte vinylpyridinderivate und arzneimittel, die diese enthalten
UY27338A1 (es) Nuevos derivados de ácido sulfónico
ATE368645T1 (de) Aminosäurederivate als hiv-protease-inhibitoren
AU8811401A (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
DE3882895D1 (de) Imid-derivate, ihre herstellung und verwendung.
CY1105939T1 (el) Παραγωγα βενζοθειαζινης και βενζοθεαδιαζινης, μεθοδος παρασκευης αυτων και φαρμακευτικες συνθεσεις οι οποιες τα πepιεχουν
ATE89739T1 (de) Entzuendungshemmende und/oder antiallergische zusammensetzung, die glutathionderivate enthaelt.
DE60302951D1 (de) Pyroglutaminsäure-salz von Amlodipin
PA8558901A1 (es) Nuevos compuestos hexaciclicos
DK0551844T3 (da) Svovlholdige galdesyrederivater
EA200100155A3 (ru) Новые производные 6-амино или 6-гидразиносульфонил-3-хинолинилфосфоновой кислоты, способ их получения и содержащие их фармацевтические композиции
ATE243219T1 (de) 9a, 11b-dehydro derivative von 9-oxime-3-keto-6-0-methylerythromycin
DE602004019508D1 (de) Diaminderivat, herstellungsverfahren und antioxidations-arzneimittel
EP1466900A4 (de) 2-substituierte vitamin-d-derivate